Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Clinical trial NCT05127954 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05127954
- Sponsor
- AbbVie
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-14
- Primary completion
- 2028-01-01
- Enrollment
- 1200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.